Bringing her extensive investment and healthcare experience, Xin will be focusing on new investment opportunities for the China Healthcare Fund, with a strong focus on therapeutics.
Xin joins Eight Roads from Greater Pacific Capital where she was Managing Director and Head of China Office, focusing on growth stage healthcare investments in China and Asia. Before that, she was Global Head of Business Development for Asia Pacific & Emerging Markets at GlaxoSmithKline in London, where she led key strategic acquisitions for the company. Prior to GSK, Xin held various senior executive roles in Hoffmann-La Roche in Switzerland and Eli Lilly in Germany.
She received her graduate and undergraduate degree in Biology, with an additional qualification in Business Administration at the University of Cologne, Germany.
Jarlon Tsang, Managing Partner and Head of China at Eight Roads Ventures said: “We are delighted to welcome Xin as a core member of the healthcare team, and Xin’s arrival is another example of Eight Roads Ventures commitment to continue to grow our leading biotech team to meet the explosive growth we foresee in the field of drug discovery in China. She is an experienced global investor and pharmaceutical veteran with extensive knowledge and the ability to identify new opportunities and support a sustainable network of healthcare investments in China.”
Xin added: “I am excited and honoured to join Eight Roads. No one is blind to the challenges and the opportunities that confront the healthcare investment sector in China, yet the underlying strengths as well as the stellar track record of Eight Roads in delivering on its strategy are clear. Eights Roads will continue to make a positive impact to the society by backing breakthrough innovations and passionate entrepreneurs. I am looking forward to playing my part in shaping that future.”
Daniel Auerbach, Senior Managing Partner and Global Head at Eight Roads Ventures said: “Over the past 20 years, Eight Roads has established a powerful global healthcare ecosystem supported by our vast network of experts and resources across China, Japan, South East Asia, Europe and the US. The arrival of Xin marks a significant moment for the China Ventures team in terms of our increasing ability to bring deep domain expertise and trace trends and investment opportunities.”
Eight Roads is one of the region’s earliest venture capital funds. Over the past decade, Eight Roads have been active in building a comprehensive healthcare ecosystem in China covering therapeutics, med tech, services and digital solutions. Today, Eight Roads has invested in 46 healthcare companies in China, including listed companies: WuXi Apptec, Innovent Biologics, Hua Medicine, Hile Bio-Tech, Denali, NKF, EyeBright and OcuMension. In 2019, Eight Roads’ portfolio companies served more than 5.6m patients and had 36 drugs approved and/or at clinical trials stage to transform patients’ lives.